PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
 
J Clin Invest. 1991 February; 87(2): 571–580.
PMCID: PMC296345

Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment.

Abstract

Erythrocytes are known to influence hemostasis. Bleeding times are prolonged in anemia and corrected by normalizing the hematocrit. We now demonstrate that intact erythrocytes modulate biochemical and functional responsiveness of activated platelets. A two-stage procedure, permitting studies of cell-cell interactions and independently evaluating platelet activation and recruitment within 1 min of stimulation, was developed. Erythrocytes increased platelet serotonin release despite aspirin treatment, enzymatic adenosine diphosphate removal, protease inhibition, or combinations thereof. The data suggested that erythrocyte enhancement of platelet reactivity can reduce the therapeutic effectiveness of aspirin. Erythrocytes metabolically modified platelet arachidonate or eicosapentaenoate release and eicosanoid formation. They promoted significant increases in cyclooxygenase and lipoxygenase metabolites upon platelet stimulation with collagen or thrombin. However, with ionophore, erythrocytes strongly reduced platelet lipoxygenation. These erythrocyte modulatory effects were stimulus-specific. Activated platelet-erythrocyte mixtures, with or without aspirin, promoted 3-10-fold increases in extracellular free fatty acid, which would be available for transcellular metabolism. Erythrocyte-induced increases in free eicosapentaenoate may contribute to antithrombotic and anti-inflammatory effects of this fish oil derivative. These results provide biochemical insight into erythrocyte contributions to thrombosis and hemostasis, and support the concept of thrombus formation as a multicellular event.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.9M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Pérez-Requejo JL, Aznar J, Santos MT, Vallés J. Early platelet-collagen interactions in whole blood and their modifications by aspirin and dipyridamole evaluated by a new method (BASIC wave). Thromb Haemost. 1985 Dec 17;54(4):799–803. [PubMed]
  • Santos MT, Vallés J, Aznar J, Pérez-Requejo JL. Role of red blood cells in the early stages of platelet activation by collagen. Thromb Haemost. 1986 Dec 15;56(3):376–381. [PubMed]
  • Marcus AJ. Eicosanoid interactions between platelets, endothelial cells, and neutrophils. Methods Enzymol. 1990;187:585–599. [PubMed]
  • Marcus AJ, Zucker-Franklin D, Safier LB, Ullman HL. Studies on human platelet granules and membranes. J Clin Invest. 1966 Jan;45(1):14–28. [PMC free article] [PubMed]
  • Reimers RC, Sutera SP, Joist JH. Potentiation by red blood cells of shear-induced platelet aggregation: relative importance of chemical and physical mechanisms. Blood. 1984 Dec;64(6):1200–1206. [PubMed]
  • HELLEM AJ, BORCHGREVINK CF, AMES SB. The role of red cells in haemostasis: the relation between haematocrit, bleeding time and platelet adhesiveness. Br J Haematol. 1961 Jan;7:42–50. [PubMed]
  • Rittenhouse SE, Allen CL. Synergistic activation by collagen and 15-hydroxy-9 alpha,11 alpha-peroxidoprosta-5,13-dienoic acid (PGH2) of phosphatidylinositol metabolism and arachidonic acid release in human platelets. J Clin Invest. 1982 Dec;70(6):1216–1224. [PMC free article] [PubMed]
  • Vedelago HR, Mahadevappa VG. Mobilization of arachidonic acid in collagen-stimulated human platelets. Biochem J. 1988 Dec 15;256(3):981–987. [PubMed]
  • Born GV, Wehmeier A. Inhibition of platelet thrombus formation by chlorpromazine acting to diminish haemolysis. Nature. 1979 Nov 8;282(5735):212–213. [PubMed]
  • Aoki N, Naito K, Yoshida N. Inhibition of platelet aggregation by protease inhibitors. Possible involvement of proteases in platelet aggregation. Blood. 1978 Jul;52(1):1–12. [PubMed]
  • Walenga R, Vanderhoek JY, Feinstein MB. Serine esterase inhibitors block stimulus-induced mobilization of arachidonic acid and phosphatidylinositide-specific phospholipase C activity in platelets. J Biol Chem. 1980 Jul 10;255(13):6024–6027. [PubMed]
  • Fox JE, Reynolds CC, Phillips DR. Calcium-dependent proteolysis occurs during platelet aggregation. J Biol Chem. 1983 Aug 25;258(16):9973–9981. [PubMed]
  • Watson SP, McNally J, Shipman LJ, Godfrey PP. The action of the protein kinase C inhibitor, staurosporine, on human platelets. Evidence against a regulatory role for protein kinase C in the formation of inositol trisphosphate by thrombin. Biochem J. 1988 Jan 15;249(2):345–350. [PubMed]
  • Lorand L, Barnes N, Bruner-Lorand JA, Hawkins M, Michalska M. Inhibition of protein cross-linking in Ca2+-enriched human erythrocytes and activated platelets. Biochemistry. 1987 Jan 13;26(1):308–313. [PubMed]
  • Allan D, Michell RH. Accumulation of 1,2-diacylglycerol in the plasma membrane may lead to echinocyte transformation of erythrocytes. Nature. 1975 Nov 27;258(5533):348–349. [PubMed]
  • Egan RW, Paxton J, Kuehl FA., Jr Mechanism for irreversible self-deactivation of prostaglandin synthetase. J Biol Chem. 1976 Dec 10;251(23):7329–7335. [PubMed]
  • Sautebin L, Caruso D, Galli G, Paoletti R. Preferential utilization of endogenous arachidonate by cyclo-oxygenase in incubations of human platelets. FEBS Lett. 1983 Jun 27;157(1):173–178. [PubMed]
  • Hamberg M. Transformations of 5,8,11,14,17-eicosapentaenoic acid in human platelets. Biochim Biophys Acta. 1980 Jun 23;618(3):389–398. [PubMed]
  • Fischer S, von Schacky C, Siess W, Strasser T, Weber PC. Uptake, release and metabolism of docosahexaenoic acid (DHA, c22:6 omega 3) in human platelets and neutrophils. Biochem Biophys Res Commun. 1984 May 16;120(3):907–918. [PubMed]
  • Kroll MH, Schafer AI. Biochemical mechanisms of platelet activation. Blood. 1989 Sep;74(4):1181–1195. [PubMed]
  • von Schacky C, Marcus AJ, Safier LB, Ullman HL, Islam N, Broekman MJ, Fischer S. Platelet-neutrophil interactions. 12S,20- and 5S,12S-dihydroxyeicosapentaenoic acids: two novel neutrophil metabolites from platelet-derived 12S-hydroxyeicosapentaenoic acid. J Lipid Res. 1990 May;31(5):801–810. [PubMed]
  • Takenaga M, Hirai A, Terano T, Tamura Y, Kitagawa H, Yoshida S. Comparison of the in vitro effect of eicosapentaenoic acid (EPA)-derived lipoxygenase metabolites on human platelet function with those of arachidonic acid. Thromb Res. 1986 Feb 1;41(3):373–384. [PubMed]
  • Needleman P, Raz A, Minkes MS, Ferrendelli JA, Sprecher H. Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties. Proc Natl Acad Sci U S A. 1979 Feb;76(2):944–948. [PubMed]
  • von Schacky C. Prophylaxis of atherosclerosis with marine omega-3 fatty acids. A comprehensive strategy. Ann Intern Med. 1987 Dec;107(6):890–899. [PubMed]
  • Leaf A, Weber PC. Cardiovascular effects of n-3 fatty acids. N Engl J Med. 1988 Mar 3;318(9):549–557. [PubMed]
  • Siess W, Siegel FL, Lapetina EG. Dihomogammalinolenic acid, but not eicosapentaenoic acid, activates washed human platelets. Biochim Biophys Acta. 1984 Sep 28;801(2):265–276. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation